{"id":"syhx2011","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SYHX2011 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.","oneSentence":"SYHX2011 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:06.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06354114","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-04","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT05753865","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)","status":"UNKNOWN","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2023-05-01","conditions":"Advanced Breast Cancer","enrollment":454},{"nctId":"NCT05274893","phase":"PHASE1","title":"A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2022-03-31","conditions":"Advanced Breast Cancer","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SYHX2011","genericName":"SYHX2011","companyName":"CSPC Ouyi Pharmaceutical Co., Ltd.","companyId":"cspc-ouyi-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SYHX2011 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}